Chabannon C, Pegourie B, Sotto J J, Hollard D
Service d'Hématologie Clinique, Hôpital Albert-Michallon, Grenoble, France.
Nouv Rev Fr Hematol (1978). 1990;32(2):165-6.
We report the positive effect of danazol on clinical and hematological data in a patient with myelofibrosis and myeloid metaplasia. Severe cytopenia was corrected within 2 months and was maintained for an additional 2-month period. Myeloid metaplasia (lymph nodes and skin lesions) was greatly reduced. The patient experienced no side effects. We propose further trials to confirm the utility of this agent in this disease.
我们报告了达那唑对一名骨髓纤维化和髓外化生患者的临床及血液学数据的积极影响。严重血细胞减少在2个月内得到纠正，并在接下来的2个月内保持稳定。髓外化生（淋巴结和皮肤病变）显著减轻。患者未出现副作用。我们建议进一步试验以证实该药物在这种疾病中的效用。
